Castle Biosciences (CSTL) Change in Accured Expenses (2018 - 2026)

Castle Biosciences has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $2.8 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $2.8 million, up 141.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 57.03% YoY), and the FY2025 annual result was $5.7 million, up 58.78% from the prior year.
• Change in Accured Expenses came in at $2.8 million for Q1 2026 at Castle Biosciences, down from $3.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.4 million in Q3 2023 to a low of -$11.6 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $160000.0 (2022), against an average of $924764.7.
• Peak annual rise in Change in Accured Expenses reached 5172.5% in 2023, while the deepest fall reached 39968.97% in 2023.
• Castle Biosciences' Change in Accured Expenses stood at -$110000.0 in 2022, then jumped by 3019.09% to $3.2 million in 2023, then surged by 52.07% to $4.9 million in 2024, then decreased by 21.56% to $3.8 million in 2025, then slipped by 28.07% to $2.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.8 million (Q1 2026), $3.8 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.